DRUG TREATMENT -PAST AND PRESENT
It is fair to say, without being specific, that much of the drug treatment of the past was met with a variety of responses ( Figure 1) . Much of the body of knowledge regarding effects of drugs was derived from qualitative observation so that it is not surprising that the responses to drug treatment were sometimes unpredictable. Unpredictable response is not just a thing of the past. Not all, indeed not many, patients respond in exactly the same way to drug treatment. Why do some patients require many times the dose of others for induction of anaesthesia with thiopentone? Why do some patients receive no pain relief from a dose of pethidine which is perfectly adequate for others? Factors influencing an individual patient's response can fall into either of two broad categories -pharmacodynamic and pharmacokinetic. We will define these factors and examine their role in clinical medicine.
Early notions for a quantitative basis of drug action can be traced to the publication of two papers by Professor Torsten Teorelp,2 in 1937 describing a mathematical relationship for the concentration of "substances in the body" with time. These were the beginnings of the discipline of pharmacokinetics. The growth rate of pharmacokinetics was slow until the ·Ph.D., Senior Lecturer. 1960s but since then the growth rate has been incredibly high as more clinicians appreciate the usefulness of pharmacokinetics in drug treatment.
Just what is pharmacokinetics and how does it differ from pharmacodynamics? Pharmacokinetics is the study of the time course of drugs and their metabolites in the body. To some, it involves the construction of mathematical relationships to interpret these data. To others, it is simply the study of what the body does to the drug and how long it takes to do it. On the other hand, pharmacodynamics is what the drug does to the body. Plainly, these are completely interdependent. While pharmacokinetics involves study of the rates of drug uptake, distribution, metabolism and excretion, pharmacodynamics is more concerned with relationships between pharmacologic response and drug concentration in biofluids. By quantitating the factors which regulate drug concentrations in the blood, pharmacokinetics offers the basis of rational, if not optimised, drug treatment ( Figure 2 ) -it is the "scientific" approach of today. DRUG FIGURE 2, GRADED RESPONSE -"The bigger the dose, the bigger the effect"
Notions developed from application of the Law of Mass Action to analysis of enzyme kinetics have been applied to the combination of drugs with their cellular receptors in the study of graded response.
The Law of Mass Action originated from studies of the kinetics of chemical reactions. Where a chemical reaction is reversible (and most are to some extent) an equilibrium is set up so that the ratio of concentrations, products to reactants is a constant. Disturbance of the equilibrium by changing the concentrations of any component will cause the system to readjust to maintain the equilibrium ratio of concentrations. This principle underlies many concepts involved with drug action such as drug-receptor combination, drug ionization and drug protein-binding.
For the majority of drugs; effects are produced by the combination of drug with some more-or-less specific area on the surface of a macromolecule which expects to receive endogenous compounds such as adrenaline or noradrenaline. Hence there is a requirement for precise physiochemical features for a drug molecule to 'fit'. The extreme specificity of some receptors requires a particular stereo isomer form* for activity and other forms may differ totally in their activity (Table 1) , e.g. D( -)-morphine IS an active analgesic, L( + )-morphine is inert; L( + )-mepivacaine exerts considerable vasoconstrictor action compared with D( -)-mepivacaine. Other times, the preciseness of drug structure is less and a variety of drugs produce the same effect, e.g. inhibition of cholinesterase or general anaesthesia. But for the majority of drugs the precise nature of their receptor is still unknown. *Stcrcoisomer forms, optical isomers or enantiamorphs differ only in the order of attachment of chemical groups to an asymmetric carbon. w. x, Y and Z arc different suhstitucnt groups bonded to the asymmetric or optk:aJly active carbon atom. The two form') arc mirror images and cannot be superimposed. The 0 and L are one (traditional) method of describing the absolute configuration by reference 10 ~tandard substances, 0-and L-glyceraldchyde. (+) and (-) indicate the direction (cJockwi~e or antido(;kwise, respectively) that the molecule rotates plane polarised light. These (WO properties are independent even among ~imilar molecules. e.g. the configuration of ( +) and (-) mepivacaine are Land D respectively but (+ ) and (-) bupiva;;aine are D and L respectively. Many drugs consist of equal amounts of the two isomers called a racemk mixture or racemate. designated by DL. The graded dose-effect (or response) relationship is similar to the curve in Figure 3 . It is described mathematically as a rectangular AnaeSlhe'>ia and Intensive Care, Vol. VIII, No. 3, Au~us[, 1980 hyperbola. Increased dose leads to increased effect due to increased drug-receptor combinations. However, maximum effect may be obtained without maximum receptor occupancy. Transformation to a logarithmic dose scale produces the familiar sigmoidshaped curve (Figure 3 ). At the same time, effect is usually transformed into a percentage of maximum effect. The mid-portion (20-80070 maximum effect) of the symmetrical log doseeffect curve can be approximated by a straight line and this gives rise to the common parlance "linear dose-response curve".
QUANTAL RESPONSE -"there exists biological variability among us"
Where the response is an all-or-none affair, the relationship between dose and effect in the population may be described by a quantal doseresponse curve, for example this is the basis for the use of MAC. *3 Suppose a new intravenous anaesthetic agent is to be tested for efficacy and safety using an animal model such as the mouse. Predefinition of end points is required, for example, anaesthetic dosedose producing a sleep-like state within a specified time (say within two minutes); toxic dosedose producing cardiovascular depression within a specified time (say five minutes) after injection; fatal dosedose producing death within a specified time (say within six hours). The time period is an essential part of the definition to tie the effect to the drug administration. Starting points can be found by injecting one animal with a known dose and observing the result. If a response is not observed, then the dose is doubled and the injection repeated in another animal, etc., until a dose is found which produces the response. Conversely, if the first animal responds, the dose is successively halved until the response does not occur. Hence a rough estimate of the dose-response relationship can be derived quickly. Precise definition comes from observation of the response frequency in groups of animals (say 10 each) tested over small increments of dose from that which consistently fails to produce a response to that which consistently produces response in all animals of the test group. A plot of percentage of animals responding versus dose will produce a distribution curve which is usually skewed to the left rather than symmetrical. Similarly, distribution curves for the toxic and fatal responses may be determined. Like most biological variables these dose effect curves will not be normally distributed unless transformed to the logarithm of the doses (Figure 4a ), i.e. a log-normal distribution. Note also from Figure 4a that the curves may overlap appreciably so that an effective dose for some may be toxic to others, a mildly toxic dose to some may be fatal to others. The distribution curves may be different (as Figure 4a ) or the same depending on the mechanism of each response. Slopes may be different for the modalities measured depending on shape of the distribution curves (a) and the mechanisms operating.
Transformation of the per cent responding to cumulative per cent responding ( Figure 4b ) versus log dose produces a family of curves similar to the sigmoid shapes described by Figure 3b . The slopes of these will be different ( Figure 4b ) or the same depending on whether the distribution curves ( Figure 4a ) were different or the same. From the cumulative curve, the dose producing an effect in a particular percentage of the population is clearly visible, e.g. effective dose in 90070 of the population, fatal dose in 50070, etc. In clinical practice, the important point is the separation of these curves. Complete separation is ideal but this does not always occur, e.g. the dose effective in 95070 of the population may well be a toxic dose in 5070. The 50070 reference point is commonly used, e.g. MAC or therapeutic index*, though it is not a good choice for the basis for drug treatment because it gives no information on the steepness of gradation. It does, however, serve as a guide for comparisons among similar drugs.
Another transform used by pharmacologists for these data is the probit plot. Pro bit is derived from probability unit and is a transform of the simple distribution curve ( Figure 4A ) into a function of the area under the curve (using appropriate tables or probit graph paper). This has the effect of linearising the sigmoid curve and facilitating inspection of the population statistics or comparing different drugs 8 • The quantal dose-response relationship very neatly illustrates the variability in response. It is a statement of the variability and does not give insight into reasons for the variability. For the vast majority of drugs, it is impossible to determine their concentations at the sites causing the response. But since the blood transports them there, the concentration occurring in the blood may provide clues to understanding, regulating and predicting the response.
BLOOD CONCENTRATION-EFFECT RELATIONSHIPS
In the clinical setting, the concern is drug action in an individual patient. If the drug *Originally defined as Fatal dose in SOOJo/Effcctivc dose in 50070; more appropriately Toxic dose in SOOJo/Effcctive dose in 50070 but best at Toxic blood concentration/Effective blood concentration (see below). tOr plasma or serum, but most precisely plasma ultrafiltrate. produces its effects reversibly and is administered in sufficient dose, then the time course of the effect might resemble that depicted in Figure 5a . The complementary picture is the blood concentration-time relationship which is the driving force for the effect. A graph of effect versus bloodt concentration is a more useful refinement of the dose-effect relationship and which is independent of time ( Figure 5b ). 
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(a) Hypothetical curves for drug effect (left axis, dotted line) and drug blood concentration (right axis, solid line) for a drug given intramuscularly. Drug effect is reversible and is shown by downward displacement representing increased effect, e.g. reduction of frequency of premature ventricular contractions by lignocaine. (b) Hypothetical log blood concentration effect curves resulting from (a). Effect may be represented as graded, (i.e. Effect = Fraction of maximum effect) or quantal (i.e. Effect = Fraction of population demonstrating the effect). The hysteresis curve represents regression of graded effect at lower blood concentrations than necessary for onset of effects. This may be caused by distribution phenomena or retention at the site of action.
If equilibration of drug in the body were rapid, then an intravenous bolus would produce the maximum effect immediately. However this does not often occur because an appreciable time is required for equilibration Anaesthesia and Intensive Care, Va/. V/lf, No. 3, August, 1980 between blood and the sites of action. In cases where the drug acts by indirect mechanisms (e.g. prolongation of prothrombin times by oral anticoagulants) then the peak effect may lag considerably behind the peak blood concentrations.
The log blood concentration-effect relationships follows the familiar sigmoid shape for both graded response (effect 0,70 maximum effect) and quantal response (effect = % of population showing the particular effect). Sometimes the onset of effects occurs at higher blood concentrations than the regression of effects (Figure 5b ). This may be caused by slow equilibration between drug in blood and sites of action. Thus drug distribution may be viewed in terms of partitioning from blood across membranes to regions where drug both combines with receptors and just simply resides (acceptors). The associations may be specific depending on precise structural features of the drug or non-specific and due simply to physical properties of the drug ( Figure 6 ).
Structurally Non-specific Association
/1 \\ FIGURE 6.-Transmembrane distribution of drug.
DRUGS AND MEMBRANES
Studies of membrane structure have accelerated during the past decades 4 and it is now appreciated that many drugs act by interacting with membranes. Irrespective of how complex the descriptions of membrane structure have become, there is a remarkable consistency in the way that membranes admit and transmit drug molecules.
Three types of membrane structures have been distinguished in the body -those consisting of: 1. several layers of cells, e.g. skin, 2. single layers of cells, e.g. intestinal epithelium, 3. layers less than one cell thick, e.g. the plasma membrane of cells or membranes of intracellular components. The first two of these involve the cell membrane as the final boundary. These membranes determine to a large extent the disposition and distribution of drugs in the body. Drugs may cross membranes by either of two processes:
1. Passive Transfer which implies that the membrane behaves as an inert solvent layer or system of aqueous channels through which the solute passes.
Specialised Transport which implies that
the membrane displays active character, transporting the solute in a manner that cannot be explained by the structure or physical properties of the membrane.
Passive Transfer
Most drugs pass through membranes by simple diffusion, i.e. their rate of transfer is directly proportional to the concentration gradient. Many penetrate as if the membrane were a simple lipoid boundary and their rate is proportional to their solubility in lipid. A number of lipid-insoluble substances cross as if the membrane were a fine sieve, smaller molecules and ions crossing faster than larger ones. Some evidence suggests that ionic charge may determine rate of transfer more than size.
Specialised Transport
A carrier concept has been advanced as a tentative explanation for the peculiar permeability of cell membranes to certain lipidinsoluble compounds. These include essential nutrients, such as glucose and amino acids, and ions such as Na + and K + • The evidence suggests a ferry principle operates whereby the carrier complexes with a substrate molecule, ferries it across to the other side of the membrane, releases it and then returns to repeat the process. There is evidence for three types of carrier mechanisms.
Active transport is an energy-requiring mechanism and is characterised by: 1. movement of the solute against a concentration gradient, 2. saturation of transport with increasing concentration of solute, 3. specificity for certain chemical structures,
competitive inhibition
substances are transported mechanism.
where two by the same Facilitated diffusion is a carrier mechanism showing all of the properties of active transport except that there is no solute movement against a concentration gradient.
Exchange diffusion occurs where the carrier also returns with substrate to the original surface and may occur when the transport system approaches saturation.
Drugs which are transported by specialised mechanisms almost invariably resemble naturally occurring body substrates.
Fick's Law
If a drug crosses a body membrane by simple diffusion, its rate of entry at steady-state is described by Fick's law and will be directly proportional to the concentration gradient, a diffusion coefficient which depends on the physicochemical properties of the drug, and the surface area available for transfer, but inversely proportional to the thickness of the membrane. Thus, by influencing the equilibrium distribution of drugs between biofluids and tissues, physicochemical properties may modulate drug action through overall drug movement in the bloodstream.
Fick's Law contains terms which are not amenable to study. But there are a number of physicochemical properties which enable us to understand the behaviour of drugs in the biological milieu.
Dissociation Constant
Most drugs are weak acids or weak bases and exist in physiological solutions as an equilibrium mixture of ionized and un-ionized species. The degree of ionization depends on both the pKa (acid dissociation constant') of the drug and the pH of the solution in which it is dissolved. Only the non-ionized form can readily penetrate a membrane by simple diffusion. When it attains steady-state distribution, the concentration is the same on both sides of the membrane. As the degree of (Figure 7 ) which will result in exacerbation of the acidosis. Marked differences in pH result in markedly uneven distribution and advantage may be taken of this in promoting renal excretion of drugs by appropriate manipulation of the pH of the urine, e.g. acidification to excrete bases such as amphetamines, basification to excrete acids like salicylates (Figure 8a and b) .
The following forms of the Henderson-Hassellbalch equations illustrate the interrelationship between pH, pKa and degree of ionization: 1.
2.
C u for an acid, pKa -pH = log ~ C j for a base, pKa -pH = log C--;;where C u , C j are concentrations of non-ionized and ionized species respectively, e.g. in plasma, an acidic drug with pKa 4.4 such as phenylbutazone exists almost totally ionized, 1 molecule un-ionized to 1000 ionized (i.e. log Cu/Cj = 3.0). In gastric juice, the same drug exists almost totally un-ionized, 1000 molecules non-ionized to 1 ionized (i.e. log Cu/C j = 3.0). Uneven distribution resulting from pH distribution may be calculated from following expressions: Hence it may be deduced that drug ionization and pH differences between plasma and gastrointestinal contents have the potential to regulate drug absorption. This is illustrated in Table 2 which shows the experimental relationship between pKa and absorption of various test substances from the small intestine of rats and which emphasises the importance of the non-ionized fraction. The same relationship also suggests that basic drugs would be secreted into the stomach. Indeed, high concentrations of the bases mepivacaine and pethidine have been found in gastric juice after parenteral administration (Le. secretion down a pH gradient). However, the physiological significance of this is probably small because the amounts of drug involved are small.
Lipid Solubility
It has been observed that some drugs are not appreciably ionized in plasma but yet penetrate body compartments at rates which are TABLE 3 Gastric absorption of barbiturates in the rat compared with their organic solvent/water partition coefficients representing lipid solubility of the non-ionized form of the barbiturates. unrelated to their actual degree of ionization. In these cases, it has been shown that the rate limiting factor is the lipid solubility of the nonionized form. Indeed, a striking parallelism is shown by lipid-to-water partition coefficient* and permeability, e.g. quinalbarbitone, thiopentone and barbitone all are totally unionized in gastric juice but are absorbed from the rat stomach at completely different rates (Table 3 ).
Protein Binding
The majority of solutes in plasma, including drug molecules, are bound to some extent by plasma proteins. The extent varies from almost o (e.g. antipyrine) to almost 100070 (e.g. warfarin) ( Table 4 ). Physicochemical properties of the solute, especially ionic charge and hydrophobic nature, are responsible for the binding. Although membranes are only permeable to un bound forms, binding acts as a transport mechanism. Binding to some proteins is stronger than to others, consequently solutes tend to equilibrate in proportion to the strength of binding and quality of binding protein.
For some drugs like bupivacaine, a high degree of binding in blood is necessary to offset extensive binding in tissues -otherwise removal from the body would be extremely slow. A higher plasma binding capacity, both strength and concentration of binding protein, across a membrane may cause uneven distribution of drug. This is one reason why bupivacaine concentrations in foetal plasma are much lower than maternal plasma after administration to the mother in labour.
However, defective protein binding, either acute, e.g. due to solutes competing, or chronic, e.g. due to protein deficiency, may give rise to completely unexpected drug action. across body membranes is the outcome of the complex equilibrium relating the degree of nonionized drug, the lipid solubility of the nonionized form and the degree which the drug is unbound to proteins or other body macromolecules. As indicated in the previous section a knowledge of the physicochemical properties of drugs enables understanding of pharmacodynamics. However useful, the view based on physicochemical properties is a static view of what is definitely a non-static system. Hence the pharmacokinetic view needs to be incorporated. Absorption Physicochemical properties set the potential for the rate of absorption of drugs from their site of administration but local factors may dominate. Absorption rate from the gastrointestinal tract is not uniform because of Anaesrhesia alld Inrensn'e Care, Vol. VllI. No. 3, August, 1980 the nature and surface area of the membranes at various levels, differences in acid/base physiology, differences in gastric content, rates of emptying and mobility and differences in regional blood flow. Although it is the most frequently used route in drug administration in general medicine, the oral route is also the most complex and the least predictable. Parenteral routes (Figure 9 ) are more predictable. Absorption after intramuscular and subcutaneous injections is primarily regulated by vascularity (rate directly proportional to blood flow), by the injection volume and concentration (higher rates with both lower volumes and lower concentrations), and by tonicity and viscosity (lower rates with both higher tonicity and viscosity) of the injectate. All of these factors act in addition to those dictated by the principal physicochemical factors of the drug. 
Bioavailability
Oral administration is also complicated by bioavailability. This is commonly defined as "the extent of absorption". However, this definition is misleading. It is more appropriately defined as the fraction of the dose reaching the systemic circulation intact. The extent of absorption reflects the fraction of dose reaching the portal circulation ( Figure 10 ). The ''first pass effect" accounts for the *Bioavailability may be estimated from either of two primary methods, i.e.
using area under blood concentration curves (AUC) or using extent of urinary excretion (A u )' i.e., for equal doses, Bioavailability = AUC drug product/ AUC standard = Au drug product! Au standard. Bioavailability may be relative or absolute. If relative, then standard refers to a comparative product; if absolute, then standard refers to intravenously administered product.
Anaesthesia and Intensive Care, Vol. VIII, No. 3, August. 1980 difference being the extraction of drug from the portal circulation by the liver en route to the systemic circulation. Historically, many drugs were described as "poorly absorbed from the gastrointestinal tract" because reponse was poor after oral administration. In fact, absorption may have been complete but the first pass effect was high. Numerically, bioavailability is the product of two factors, the percentage dose passing the gut wall intact (remembering that some drugs, e.g. chlorpromazine, are metabolised by gut wall enzymes or intestinal micro-organisms) and the percentage dose escaping first pass extraction by the liver. Bioavailability' can, and does, vary from 0-100070 even among similar drugs (Table  5 ) and may be elevated in patients with liver disease giving exaggerated effects (Table 6 ). However, a low bioavailability does not always mean a poor response. The action of some drugs, in fact, is through metabolites while for others their metabolites may simply augment activity, be totally inactive or have entirely different activity (Table 7) . Drugs administered for their action through metabolite production are called pro-drugs. A high bioavailability does not always mean good response because the rate of entry of drug into the systemic circulation is also important. The absorption rate may be so slow as to preclude effect because the drug blood concentration may not exceed the minimum required for useful effect (Figure 11 ). Absorption rate may be limited by the effects of the drug itself, e.g. sympathomimetics reducing local blood flow, or narcotics inhibiting gastric emptying, by the drug formulation, e.g. a slowly releasing TABLE 5 preparation or by the drug precipitating in the fluids at the site of application and taking appreciable time to redissolve, e.g. intramuscular injections of phenytoin. Bioequivalence takes into account variables associated with the product and dosage form as well as relates equality of effects rather than blood concentrations. Issues associated with bioavailability and absorption rates are precluded if the drug is given intravenously. The mechanistic view (Figure 9) shows plainly that the drug will be distributed according to the fractional cardiac output to each tissue. The time required for each organ to equilibrate with the blood concentration (i.e. when the emergent venous concentration equals the input arterial concentration) is directly proportional to the capacity of each organ to take up drug (i.e. tissue mass x tissue: blood partition coefficient) and inversely proportional to the blood flow to the organ. This is the principle of the Kety-Schmidt method of determining cerebral blood flow. cardiac output and peak almost instantly after injection. Because of the range of transit times through the lungs and lung uptake the concentration in the systemic arterial circulation peaks some seconds after the peak in the pulmonary artery and before division into the fractional cardiac output. Drugs successively equilibrate in and redistribute from the small vessel-rich organs, the muscles and finally fat where they are likely to be more soluble (Figure 12 ). This progression, together with the processes of drug elimination, * accounts for the shape of the blood concentration-time profile. 
DRUG DISPOSITIONt
Drug is lost from the systemic circulation simultaneously by both distribution into tissues and elimination. Whereas elimination is irreversible, distribution represents temporary translocation due to tissue partition and does not contribute to drug clearance.
Compartment Models
Compartment models are a convenient method to describe disposition kinetics because they introduce relative simplicity and order into an incredibly complex problem. Mathematical descriptions for the time course of diffusible tracer substances in interconnected pools are well known to physiologists and engineers. *Flimina!ion -= metabolism + excretion. tDisposition ::::; distribution + elimination. 1Time appears as the exponent.
§Rate is directly proportional to amount of drug remaining in the body (providing saturation of eliminating mechanisms does not occur). This should be compared to a zero order process where the rate is the same irrespective of how much is there, e.g. most drug infusions are zero order because they proceed at the same rate (mg/min, etc.) irrespective of the contents of the reservoir, but drug absorption after IM injection is usually first order, i.e. a constant fraction of the amount remaining in the depot is absorbed per unit time.
Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 Application of compartment models to drugs s . 7 is based on the use of empirical mathematical equations to simulate the time course of drugs in the body. From the constants of the equation (which is usually a polyexponential, describing the sum of a number of first order processes §) the parameters of a particular compartment model which simulates the drug behaviour can be derived. The model parameters then replace the drug concentration data and these can be used in two important ways. First, they can be used to compare drug disposition, i.e. one drug with another, one patient with another, effects of disease, etc.. Second, they can be used to predict drug concentrations under other conditions, e.g. multiple dose or alternative route of administration. Compartment models utilise two major properties, compartment volume and rate constant of drug transfer into and out of that compartment. From the product of these, mass transfer of drug can be calculated.
However, there tends to be some misunderstanding about compartment models, especially with regard to 'how many compartments for a particular drug'. For any drug there are as many compartments as there are organs of different blood flow and drug tissue: blood partition coefficients. For any model of more than several compartments the mathematics is quite complex; furthermore the necessity for such a complex model is rarely justified. The appropriate 'number of compartments' is derived from the blood concentration-time curve from intravenous injection. A linear log concentration-time relationship over all of the time range from immediately after injection until much later indicates that the drug rapidly equilibrates and the whole body behaves as one homogenous compartment towards that drug, e.g. indocyanine green and antipyrine. A minority of drugs behave this way. The majority of drugs show a curved log concentration-time relationship indicating appreciably slow equilibration between blood and tissues. This kind of concentration-time relationship requires that at least two exponential equations be summed to fit the data, each one representing a compartment, i.e. one central and a peripheral compartment. But how many more than two can be confusing. If concentrations (especially arterial) are measured soon and frequently after IV bolus, then three or even four exponentials may be required to fit a line through the data points (as judged by eye and the sum of residuals 8 ). However, the more exponentials used, then the more the final model departs from being unique, i.e. a variety of reasonably similar models could be derived from the same data. The frequency and times of blood sampling are also important. If samples are not taken soon after dosing, the re-equilibration might be missed and the drug erroneously described as 'one compartment'. If samples are few, especially during curvature, then statistical considerations dictate that a more complex model cannot be substantiated even though the line of best fit seems to warrant it. Most polyexponential equation models can be represented by a two-compartment system with reasonable precision and from a reasonable number of blood samples and without the need for inordinately complex calculations, i.e. the other peripheral compartments are lumped together as being indistinguishable. Hence the two or three "compartness" of a particular drug is not really a big issue -the difference simply may be related to statistical considerations and the experimental design. Most parameters (see below) of a two compartment system cannot be compared with those of a three compartment system -the important exceptions being clearance which can be derived independently of the particular model from the Fick Principle and volume of distribution at steady-state which can be derived empirically from the exponential equation. Terminal half-life will be model independent only if sufficient data points are taken to characterise it over two or more halflives.
Drug Distribution
The extent of distribution can be estimated from the apparent volumes of distribution of which there are several kinds. The initial dilution volume* is the ratio of the dose to blood concentration immediately after injection assuming negligible lung transit time. This will vary according to where the blood is sampled: if arterial, then dilution and mixing in "'Sometimes called the central compartment volume. blood and lung uptake contribute principally; if venous, then the initial dilution volume will be much larger due to further tissue uptake. Equilibration with tissues is reflected by volume oj distribution at steady-state. This is defined by the ratio of amount of drug in the body: concentrations in blood at equilibrium if the drug were infused to a steady state. This can be calculated mathematically after bolus administration and is independent of whether the blood sample is arterial or venous. The difference between steady-state and initial volumes gives an indication of relative tissue uptake of the drug. Extrapolated volume oj distribution is the equivalent of volume derived from a one compartment system. It is sometimes used to indicate the ratio of amount of drug remaining in body: blood concentration during the phase of pseudo-equilibrium occurring after the redistribution phase when blood concentrations are declining at a constant rate after completion of IV administration.
It should be emphasised that all volumes of distribution are hypothetical or apparent body spaces which are useful to express mathematically the relationship between blood concentration and dose or blood concentration and amount of drug in the body. They can be used to calculate doses to produce a given blood concentration but rarely do they represent anatomical spaces. Hence, the initial dilution volume, even with arterial sampling, does not reflect the blood volume because the blood does not behave like a separate body compartment to most drugs. Mixing in blood is not instantaneous as evidenced from peaks and recirculation peaks occurring after administration of diagnostic dyes. Filtration and diffusion out of the capillary beds occur while mixing is still taking place, giving rise to an initial dilution volume in excess of, but containing, the blood volume. Some few substances, however, do distribute into defined anatomical spaces. These are called "marker substances" and their appropriate apparent volumes of distribution (some require appreciable equilibration time) do measure true body compartment volumes or spaces, e.g. dilution of deuterium oxide or antipyrine has been used to measure total body water; plasma volume may be estimated with Evans Blue, 1 131 -tagged albumin or Cr 51 -tagged Anaesthesia and Intensive Care, Vol. VUI, No. 3, August, 1980 erythrocytes; total extracellular water has been estimated by dilution of Cps, bromide or thiocynate. Formulae for the calculation of distribution volumes are given elsewhere. slO
Drug Clearance
Total body clearance measures the efficiency of drug removal from the body. It can be derived from application of the Fick Principle to blood concentration-time data after intravenous bolus or infusion from the ratio of dose to the total area under blood concentration-time curve. * The area under the curve is not affected by distribution because drug lost to tissue while the concentration gradient from blood is high will be regained when the gradient is reversed.
The proportional rate of removal (rate constant) of a drug from the body depends on the actual volume being cleared. Thus clearance (which has the units of volume/time) can be derived from the product of the rate constant and the volume from which the drug is being removed. Under these circumstances clearance can be equated to a virtual flow. This has exactly the same effect as washing drug out of a fixed volume by a continuous dilution using a real flow equal to the clearance.
The action of the majority of drugs is terminated by metabolism, excretion or both, -the proportions depending on the individual drug e.g. propranolol is about 95070 metabolised, practolol is about 95% excreted in urine unchanged, procainamide is about 50% of each.
Rationale for the pharmacokinetic concept of renal clearance has been borrowed from the physiologists and is described as the 'volume of plasma totally cleared of drug per unit time into the urine'. Hence the ratio of urinary excretion rate to plasma concentration at the mid-point of the urine collection interval gives the renal clearance. Alternatively, a graph prepared from a number of these estimates has renal clearance as its slope. Renal clearance can be determined also from the product of fraction of dose excreted in urine and the total body clearance. If the drug were excreted into urine totally *This can be calculated mathematically. e.g. using the trapezoidal rule or measured mechanically, e.g. using a planimeter. tOflen called "plasma half-life" or just "half-life", more precisely "slow half-life" as compared to "fast (and intermediate) half-life" which describe the redistribution phase(s), without metabolic alteration, the amount of drug remaining in the body would decrease at exactly the same rate as the amount excreted in urine increased ( Figure 13 ). The difference between the total body clearance and the renal clearance is referred to as "non-renal clearance". For most drugs this is synonymous with hepatic clearance but for a few drugs of interest to the anaesthetist it also comprises plasma enzymes (e.g. procaine, propanidid) and lung enzymes (e.g. isoprenaline, prilocaine).
Amount in Body IABI
TIME
Hepatic clearance is the major determinant of oral bioavailability. Since bioavailability measures the fraction of dose escaping first pass hepatic extraction (hepatic extraction = hepatic clearance/hepatic blood flow), it follows that drugs with high hepatic clearance will always have low oral bioavailability. Impaired clearance, either hepatic or renal, will lead to abnormally high drug concentrations with the distinct likelihood of exaggerated or unexpected response.
Half-Life
Half-life is the time required for blood concentration to change by a factor of 2 (increase during infusion, decrease after bolus or cessation of infusion). If distribution in the body takes appreciable time, then the half-life for the "distribution phase(s}" may be given also. As time increases the contribution due to distribution becomes increasingly less and the change in blood concentrations will eventually be described by a single terminal half-life. t This then characterises the rate of drug removal from the body. The terminal half-life also governs the rate of accumulation on constant rate infusion.
Intravenous Infusion
Intermittent dosing of drugs generates fluctuating blood concentrations and therefore fluctuating response. This is accentuated if the blood concentration-response curve is steep and the drug half-life is short. Intravenous infusion minimises the fluctuation in response by abolishing the peaks and troughs of blood concentrations.
If the body is infused continuously, the blood concentrations will increase until a plateau is reached at steady-state. This means that the rate of drug input is balanced by the rate of drug elimination, and distribution is complete. The theory underlying steady-state is very well developed but beyond the scope of the present paper. 1 1 After infusion for one (terminal) halflife, 50070 of the ultimate steady-state concentration (C ss = infusion rate/clearance) is obtained; after two half-lives of infusion 50070 of the remaining gap to C ss is obtained (i.e. 75070 C ss ), after three half-lives 50070 of that remaining (i.e. 87.5070 C ss ) etc. In theory, C ss is only obtained after an infinitely long infusion in the same way that zero concentration is obtained only after an infinite period after cessation of administration. In practice, 97070 of both is completed in five half-lives and this is generally considered near enough to being complete. The venous concentration lags behind the arterial drug concentration due to the time required for equilibration between tissue and blood ( Figure 14 ). However, venous blood from eliminating organs will never be the same as arterial or venous blood from other tissues. 
DRUG TREATMENT -FUTURE?
If every patient responded in the same way to drug treatment there would be no need for much of the medical literature and many pharmacologists would be out of work. But patients do not respond alike. Many factors contribute to the variability among patients. Some of these are labelled pharmacodynamic factors and are related to the response that occurs when a dose of drug is sent on its way to tingle the receptors as well as the way that the individual patient processes his biological signals. Other factors are more tangible. These are pharmacokinetic factors and can be measured by the rates and extent that the individual patient absorbs, distributes, metabolizes and excretes his drug supply. As far as blood concentrations mirror drug concentrations at the sites of action, then pharmacokinetic factors may explain or even predict responses by allowing control over the blood concentrations of drug.
What about drug treatment in the future? Logic suggests that since drugs are administered to attain a particular action or response rather than a particular concentration in the blood or biofluids, then efforts should be made to finely tune that response (Figure 15 ). Before this can happen we need to learn more about biological signals, their control and how to couple them to a logic device which will make decisions on starting and stopping drug administration to regulate response. This methodology already has been applied to the regulation of muscle relaxation 12.13 which involves a very clear response. When more of the interpretive skills of the anaesthetist have been committed to computer memory we may see a time when the anaesthesia for a group of operating rooms is run by one electronic engineer and a computer. At that stage there will be no need for pharmacokinetics and pharmacodynamics and we will do as did the clinicians of old -but with a lot more predictable response. 
